MDSCs在肿瘤免疫治疗中的研究进展

doi:10.20223/j.cnki.1000-8535.2025.02.002

摘要/Abstract

摘要： 实体瘤对免疫治疗应答非常有限,因此,如何有效提升肿瘤免疫治疗的疗效,已成为当前肿瘤免疫治疗领域亟待解决的关键难题与挑战。髓系来源抑制性细胞（MDSCs）的趋化募集及其所介导的肿瘤免疫逃逸机制,是制约实体瘤免疫治疗效果的核心因素之一。文章深入探讨了MDSCs的起源、表型特征、其介导肿瘤免疫逃逸的具体机制,以及当前针对MDSCs的靶向治疗策略与将MDSCs靶向疗法与肿瘤免疫治疗相结合的最新研究进展。此外,文章还系统性地分析了靶向MDSCs联合免疫治疗策略所面临的关键挑战,并据此提出了MDSCs的精准靶向策略。这一策略旨在精确激活抗肿瘤免疫反应,为癌症患者提供更为个性化、高效的治疗方案,从而开启肿瘤免疫治疗领域的新纪元,为癌症治疗策略的创新与发展贡献力量。

关键词: 肿瘤免疫治疗, 免疫逃逸, 髓系来源抑制性细胞, 联合治疗

Abstract: Solid tumors exhibit a very limited response to immunotherapy．Consequently,effectively enhancing the therapeutic efficacy of tumor immunotherapy has emerged as a critical challenge and problem that urgently needs to be addressed in tumor immunotherapy．The chemotaxis and recruitment of myeloid-derived suppressor cells（MDSCs）and the tumor immune evasion mechanisms mediated by them are one of the core factors that significantly restrict the efficacy of immunotherapy for solid tumors．In this review,we discuss the origins and phenotypic characteristics of MDSCs,the specific mechanisms by which they mediate tumor immune evasion,as well as current targeted therapeutic strategies for MDSCs and the latest research progress in combining MDSC-targeted therapy with tumor immunotherapy．Furthermore,we have systematically analyzed the key challenges faced by the combination of MDSC-targeted and immunotherapy strategies,and accordingly proposed a precise targeting strategy for MDSCs．This strategy aims to precisely activate anti-tumor immune responses,providing more personalized and efficient treatment options for cancer patients,thereby opening a new era in tumor immunotherapy and contributing to the innovation and development of cancer treatment strategies．

Key words: tumor immunotherapy, immune evasion, myeloid-derived suppressor cells（MDSCs）, combination therapy

姚远, 尹亭亭. MDSCs在肿瘤免疫治疗中的研究进展[J]. 广州医药, 2025, 56(2): 151-159.

YAO Yuan, YIN Tingting. Research progress of MDSCs in tumor immunotherapy[J]. Guangzhou Medical Journal, 2025, 56(2): 151-159.

参考文献

[1] ZHANG Y,ZHANG Z.The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J].Cell Mol Immunol,2020,17(8):807-821.
[2] WEI G,ZHANG H,ZHAO H,et al.Emerging immune checkpoints in the tumor microenvironment:Implications for cancer immunotherapy[J].Cancer Lett,2021(511):68-76.
[3] SIU L L,IVY S P,DIXON E L,et al.Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies[J].Clin Cancer Res,2017,23(17):4950-4958.
[4] BEATTY G L,GLADNEY W L.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
[5] VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35 Suppl:S185-S98.
[6] PAN Y,YU Y,WANG X,et al.Tumor-Associated Macrophages in Tumor Immunity[J].Front Immunol,2020(11):583084.
[7] TOGASHI Y,SHITARA K,NISHIKAWA H.Regulatory T cells in cancer immunosuppression - implications for anticancer therapy[J].Nat Rev Clin Oncol,2019,16(6):356-371.
[8] WU Y,YI M,NIU M,et al.Myeloid-derived suppressor cells:an emerging target for anticancer immunotherapy[J].Mol Cancer,2022,21(1):184.
[9] GABRILOVICH D I,NAGARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J].Nat Rev Immunol,2009,9(3):162-174.
[10] KUMAR V,PATEL S,TCYGANOV E,et al.The nature of myeloid-derived suppressor cells in the tumor microenvironment[J].Trends Immunol,2016,37(3):208-220.
[11] MARIGO I,BOSIO E,SOLITO S,et al.Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor[J].Immunity,2010,32(6):790-802.
[12] QIAN B Z,LI J,ZHANG H,et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J].Nature,2011,475(7355):222-225.
[13] YOUN J I,NAGARAJ S,COLLAZO M,et al.Subsets of myeloid-derived suppressor cells in tumor-bearing mice[J].J Immunol,2008,181(8):5791-5802.
[14] ELLIOTT L A,DOHERTY G A,SHEAHAN K,et al.Human tumor-infiltrating myeloid cells:phenotypic and functional diversity[J].Front Immunol,2017(8):86.
[15] YOUN J I,COLLAZO M,SHALOVA I N,et al.Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice[J].J Leukoc Biol,2012,91(1):167-181.
[16] GABRILOVICH D I,OSTRAND-ROSENBERG S,BRONTE V.Coordinated regulation of myeloid cells by tumours[J].Nat Rev Immunol,2012,12(4):253-268.
[17] ZHANG H,MARIC I,DIPRIMA M J,et al.Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J].Blood,2013,122(7):1105-1113.
[18] NOMAN M Z,DESANTIS G,JANJI B,et al.PD-L1 is a novel direct target of HIF-1alpha,and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J].J Exp Med,2014,211(5):781-790.
[19] LU C,REDD P S,LEE J R,et al.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells[J].Oncoimmunology,2016,5(12):e1247135.
[20] DENG J,LI J,SARDE A,et al.Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment[J].Cancer Immunol Res,2019,7(7):1079-1090.
[21] LIMAGNE E,RICHARD C,THIBAUDIN M,et al.Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients[J].Oncoimmunology,2019,8(4):e1564505.
[22] RODRIGUEZ P C,QUICENO D G,OCHOA A C.L-arginine availability regulates T-lymphocyte cell-cycle progression[J].Blood,2007,109(4):1568-1573.
[23] SRIVASTAVA M K,SINHA P,CLEMENTS V K,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[J].Cancer Res,2010,70(1):68-77.
[24] PLATTEN M,WICK W,van DEN EYNDE B J.Tryptophan catabolism in cancer:beyond IDO and tryptophan depletion[J].Cancer Res,2012,72(21):5435-5440.
[25] OSTRAND-ROSENBERG S,SINHA P.Myeloid-derived suppressor cells:linking inflammation and cancer[J].J Immunol,2009,182(8):4499-506.
[26] BRONTE V,BRANDAU S,CHEN S H,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J].Nat Commun,2016(7):12150.
[27] FENG S,CHENG X,ZHANG L,et al.Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers[J].Proc Natl Acad Sci U S A,2018,115(40):10094-10099.
[28] SINHA P,CLEMENTS V K,BUNT S K,et al.Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response[J].J Immunol,2007,179(2):977-983.
[29] LI J,WANG L,CHEN X,et al.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer[J].Oncoimmunology,2017,6(6):e1320011.
[30] HAN B,MAO F Y,ZHAO Y L,et al.Altered NKp30,NKp46,NKG2D,and DNAM-1 Expression on circulating NK cells is associated with tumor progression in human gastric cancer[J].J Immunol Res,2018(2018):6248590.
[31] GUJAR S A,CLEMENTS D,DIELSCHNEIDER R,et al.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms[J].Br J Cancer,2014,110(1):83-93.
[32] VINCENT J,MIGNOT G,CHALMIN F,et al.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J].Cancer Res,2010,70(8):3052-3061.
[33] NAGARAJ S,YOUN J I,WEBER H,et al.Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J].Clin Cancer Res,2010,16(6):1812-1823.
[34] SERAFINI P,MECKEL K,KELSO M,et al.Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function[J].J Exp Med,2006,203(12):2691-2702.
[35] LI L,WANG L,LI J,et al.Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer[J].Cancer Res,2018,78(7):1779-1791.
[36] SHAYAN G,KANSY B A,GIBSON S P,et al.Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals[J].Clin Cancer Res,2018,24(1):62-72.
[37] KUSMARTSEV S,CHENG F,YU B,et al.All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination[J].Cancer Res,2003,63(15):4441-4449.
[38] MIRZA N,FISHMAN M,FRICKE I,et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients[J].Cancer Res,2006,66(18):9299-9307.
[39] SANSONE P,BROMBERG J.Targeting the interleukin-6/Jak/stat pathway in human malignancies[J].J Clin Oncol,2012,30(9):1005-1014.
[40] KO J S,RAYMAN P,IRELAND J,et al.Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J].Cancer Res,2010,70(9):3526-3536.
[41] FLEET J C,BURCHAM G N,CALVERT R D,et al.1alpha,25 Dihydroxyvitamin D(1,25(OH)(2)D)inhibits the T cell suppressive function of myeloid derived suppressor cells(MDSC)[J].J Steroid Biochem Mol Biol,2020(198):105557.
[42] YU S J,MA C,HEINRICH B,et al.Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma[J].J Hepatol,2019,70(3):449-457.
[43] SUN R,LUO H,SU J,et al.Olaparib suppresses MDSC recruitment via SDF1alpha/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice[J].Mol Ther,2021,29(1):60-74.
[44] LIU Y,SUN Y,WANG P,et al.FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer[J].J Transl Med,2023,21(1):255.
[45] BINNEWIES M,ROBERTS E W,KERSTEN K,et al.Understanding the tumor immune microenvironment(TIME)for effective therapy[J].Nat Med,2018,24(5):541-550.
[46] MEYER C,CAGNON L,COSTA-NUNES C M,et al.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab[J].Cancer Immunol Immunother,2014,63(3):247-257.
[47] WEBER J,GIBNEY G,KUDCHADKAR R,et al.Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after Ipilimumab[J].Cancer Immunol Res,2016,4(4):345-353.
[48] LAU J,CHEUNG J,NAVARRO A,et al.Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice[J].Nat Commun,2017(8):14572.
[49] TANG H,LIANG Y,ANDERS R A,et al.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression[J].J Clin Invest,2018,128(2):580-588.
[50] KIM K,SKORA A D,LI Z,et al.Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells[J].Proc Natl Acad Sci U S A,2014,111(32):11774-11779.
[51] WEBER R,GROTH C,LASSER S,et al.IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy[J].Cell Immunol,2021(359):104254.
[52] JIN K,PANDEY N B,POPEL A S.Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis[J].Breast Cancer Res,2018,20(1):54.
[53] MACE T A,SHAKYA R,PITARRESI J R,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
[54] HIGHFILL S L,CUI Y,GILES A J,et al.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J].Sci Transl Med,2014,6(237):237ra67.
[55] TU M M,ABDEL-HAFIZ H A,JONES R T,et al.Inhibition of the CCL2 receptor,CCR2,enhances tumor response to immune checkpoint therapy[J].Commun Biol,2020,3(1):720.
[56] GORDY J T,SANDHU A K,FESSLER K,et al.IFNalpha and 5-Aza-2’-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model[J].Front Immunol,2022(13):1074644.
[57] PENG D,TANIKAWA T,LI W,et al.Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling[J].Cancer Res,2016,76(11):3156-3165.
[58] WAN S,ZHAO E,KRYCZEK I,et al.Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J].Gastroenterology,2014,147(6):1393-1404.
[59] WANG P F,SONG S Y,WANG T J,et al.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies:A meta-analysis of 40 studies[J].Oncoimmunology,2018,7(10):e1494113.
[60] NAKAMURA K,SMYTH M J.Myeloid immunosuppression and immune checkpoints in the tumor microenvironment[J].Cell Mol Immunol,2020,17(1):1-12.